無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

放出制御ドラッグデリバリーの世界市場:市場機会・臨床パイプラインの分析・予測 (〜2025年)

Global Controlled Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025

発行 KuicK Research 商品コード 749539
出版日 ページ情報 英文 700 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.61円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
放出制御ドラッグデリバリーの世界市場:市場機会・臨床パイプラインの分析・予測 (〜2025年) Global Controlled Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025
出版日: 2018年11月21日 ページ情報: 英文 700 Pages
概要

当レポートでは、世界の放出制御ドラッグデリバリーの市場を調査し、市場の定義と概要、市場の発展の経緯、放出制御のメカニズム・技術・アプローチ、市場成長への影響因子および市場機会の分析、放出制御薬の臨床パイプラインおよび上市済み薬剤の動向、主要事業者のプロファイル、将来の展望などをまとめています。

第1章 ドラッグデリバリー:成長の軌道

第2章 放出制御ドラッグデリバリーとは

第3章 放出制御ドラッグデリバリー技術の開発

  • 第一世代
  • 第二世代

第4章 放出制御ドラッグデリバリーの基礎情報

  • 放出制御ドラッグデリバリーの前提条件
  • 放出制御ドラッグデリバリーの合理性

第5章 放出制御のメカニズム

  • 拡散律速
  • 溶解律速
  • 水の浸透による律速
  • 侵食 (エロージョン) による律速
  • イオン交換による律速

第6章 放出制御ドラッグデリバリーの分類

  • デリバリーシステム別
  • 技術別
  • 経路別

第7章 放出制御ドラッグデリバリーの各種アプローチ

  • ポリマー
  • 時間製剤学 (Chronopharmaceutics)
  • ナノ粒子デリバリーシステム

第8章 放出制御薬の臨床パイプライン:概要

  • フェーズ別
  • 国・地域別
  • 作用機序別
  • 薬剤クラス別
  • 適応症別

第9章 放出制御ドラッグデリバリーの各種用途

  • 糖尿病
  • 心血管疾患
  • 神経系疾患
  • 感染症

第10章 放出制御薬の設計

  • 経腸製剤
    • 固形剤
    • 液体剤
    • 吸入剤
  • 非経口剤
    • 注射剤
    • 植込みデバイス
  • 薬剤放出の一般的メカニズム

第11章 市場傾向

  • 投薬経路
  • アプローチ

第12章 市場力学

  • 推進因子
  • 課題

第13章 将来の展望

  • 進行中の臨床試験
  • 将来の市場機会

第14章 臨床試験:企業・適応症・フェーズ別

  • 不明
  • 研究段階
  • 前臨床段階
  • 臨床段階
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 申請済み
  • 承認済み

第15章 上市済み薬剤

第16章 競合環境

  • Allergan
  • Amylin Pharmaceuticals
  • AstraZeneca
  • BioAlliance Pharma
  • Biogen
  • Collegium Pharmaceutical
  • Controlled Therapeutics (Ferring Pharmaceuticals)
  • Cosmo Pharmaceuticals
  • Egalet
  • Elan Corporation
  • Encore Therapeutics
  • Flamel Technologies
  • GlaxoSmithKline
  • Heron Therapeutics
  • iCeutica
  • Mithra Pharmaceuticals
  • Neurim Pharmaceuticals
  • Novartis
  • Orexigen Therapeutics
  • 大塚製薬
  • Pfizer
  • Purdue Pharma
  • Syntex Pharmaceuticals International
  • 武田薬品工業
  • Zealand Pharma
目次

"Global Controlled Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025" Report Highlights:

  • Development of Controlled Drug Delivery Technology
  • Approaches for Controlled Drug Delivery
  • Global Controlled Release Drug Clinical Pipeline by Phase, Indication, Drug Class
  • Global Controlled Release Drug Clinical Pipeline: 218 Drugs
  • Marketed Controlled Release Drugs: 118 Drugs
  • Majority Drugs In Phase-II & Phase-III Trials: More Than 80
  • Global Controlled Drug Delivery Market Future Outlook

Controlled drug delivery technology is the one of the most rapidly advancing area in human healthcare management and already had an enormous impact on medical technology with the potential to improve health. As the goal of any drug delivery system is to provide a therapeutic amount of drug to a proper site in the body so that the desired drug concentration can be achieved promptly and then maintained, all these characteristics are provided by controlled drug delivery technologies.

Controlled drug delivery systems provide uniform concentration of drug to the absorptions site and thus allow the maintenance of plasma concentration within the therapeutic range which minimizes not only the side effects but also the frequency of administration. The term controlled release has a meaning that goes beyond the scope of sustained drug action.

One of the major factors for the increased market tendencies for controlled drug delivery market is the improvement and advances in the use of varied approaches. Polymeric controlled drug delivery is the most applied strategy towards the controlled drug delivery. Polymers used for coating and in other forms consist of two forms synthetic and biodegradable polymers. The extensive usage of biodegradable polymers in medical devices is expected to push the global biodegradable polymers market.

The future of controlled drug delivery is quite fertile with respect to various upcoming systems and products which will be providing the controlled release mechanism. Some of the products have been launched and some will be coming soon as are under clinical investigations. Various depot systems are under construction, along with the approaches using nanoparticulate system, transdermal controlled deliveries and much more. Newer, more sophisticated, transdermal patches and other transdermal controlled drug delivery systems are being developed that are currently being tested in clinical trials.

KuicK Research report on the "Controlled Release Drug Delivery Market" is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, superiority of Controlled Drug Delivery methods to traditional drug delivery methods. The report also provides key insights into the technology and approaches of controlled delivered drugs, recent developments and market dynamics that might impact its future. The report concludes with comprehensive insight on ongoing clinical trials of controlled delivered drugs and future trends which clearly highlights it as one of the most promising market in the modern drug delivery segment.

Table of Contents

1. Drug Delivery: An Advancing Trajectory

  • 1.1. Preamble Towards Drug Delivery
  • 1.2. Ideal Mode of Drug Delivery System

2. What is Controlled Drug Delivery?

  • 2.1. Novel Drug Delivery Systems
  • 2.2. Preamble to Controlled Drug Delivery

3. Development of Controlled Drug Delivery Technology

  • 3.1. First Generation
  • 3.2. Second Generation

4. Basics of Controlled Drug Delivery

  • 4.1. Prerequisites of Controlled Delivery
  • 4.2. Rationale for Controlled Drug Delivery

5. Mechanism of Controlled Drug Release

  • 5.1. Diffusion Controlled
  • 5.2. Dissolution Controlled System
  • 5.3. Water Penetration Controlled System
  • 5.4. Erosion Controlled System
  • 5.5. Ion-Exchange Controlled System

6. Cataloging of Controlled Drug Delivery

  • 6.1. Classification Based Over Delivery Systems
  • 6.2. Classification Based Over Technicality
  • 6.3. Classification Based Over Routes

7. Approaches for Controlled Drug Delivery

  • 7.1. Polymers
  • 7.2. Chronopharmaceutics
  • 7.3. Nanoparticulate Delivery System

8. Global Controlled Release Drug Clinical Pipeline Overview

  • 8.1. Phase
  • 8.2. Country/Region
  • 8.3. Mode of Action
  • 8.4. Drug class
  • 8.5. Indication

9. Application of Controlled Drug Delivery

  • 9.1. Diabetes
  • 9.2. Cancer
  • 9.3. Cardiovascular Diseases
  • 9.4. Neurological Disorders
  • 9.5. Infections

10. Drug Designing for Controlled Delivery

  • 10.1. Enteral Dosage Formulations
    • 10.1.1. Solid Dosage Forms
    • 10.1.2. Liquid Dosage Forms
    • 10.1.3. Inhalation Dosage Forms
  • 10.2. Parenteral Dosage Forms
    • 10.2.1. Injectable Dosage Forms
    • 10.2.2. Implantable Device
  • 10.3. General Mechanisms of Drug Release

11. Market Inclinations

  • 11.1. Market over Routes of Administration
  • 11.2. Market over Approaches

12. Global Controlled Drug Delivery Market Dynamics

  • 12.1. Accelerative Parameters
  • 12.2. Challenges

13. Global Controlled Drug Delivery Market Future Outlook

  • 13.1. Ongoing Clinical Trials
  • 13.2. Future Market Opportunities

14. Global Controlled Drug Delivery Clinical Trials by Company, Indication and Phase

  • 14.1. Unknown
  • 14.2. Research
  • 14.3. Preclinical
  • 14.4. Clinical
  • 14.5. Phase-I
  • 14.6. Phase-I/II
  • 14.7. Phase-II
  • 14.8. Phase-II/III
  • 14.9. Phase-III
  • 14.10. Preregistration
  • 14.11. Registered

15. Marketed Controlled Release Drug Clinical Insight by Company, Indication and Phase

16. Competitive Landscape

  • 16.1. Allergan
  • 16.2. Amylin Pharmaceuticals
  • 16.3. AstraZeneca
  • 16.4. BioAlliance Pharma
  • 16.5. Biogen
  • 16.6. Collegium Pharmaceutical
  • 16.7. Controlled Therapeutics (Ferring Pharmaceuticals)
  • 16.8. Cosmo Pharmaceuticals
  • 16.9. Egalet
  • 16.10. Elan Corporation
  • 16.11. Encore Therapeutics
  • 16.12. Flamel Technologies
  • 16.13. GlaxoSmithKline
  • 16.14. Heron Therapeutics
  • 16.15. iCeutica
  • 16.16. Mithra Pharmaceuticals
  • 16.17. Neurim Pharmaceuticals
  • 16.18. Novartis
  • 16.19. Orexigen Therapeutics
  • 16.20. Otsuka Pharmaceutical
  • 16.21. Pfizer
  • 16.22. Purdue Pharma
  • 16.23. Syntex Pharmaceuticals International
  • 16.24. Takeda
  • 16.25. Zealand Pharma

List of Figures

  • Figure 1-1: Characteristics of an Ideal Drug Delivery System
  • Figure 2-1: Limitations of the Conventional Drug Delivery Systems
  • Figure 2-2: Diversification of the Novel Drug Delivery Platforms
  • Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
  • Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
  • Figure 4-1: Demonstration of the Targeted & Non-Targeted Drug Delivery
  • Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
  • Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
  • Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
  • Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
  • Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
  • Figure 6-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
  • Figure 6-2: Comparison of Varied Modified Drug Release Systems
  • Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
  • Figure 6-4: Classification Based Over the Technicality Erudition
  • Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
  • Figure 6-6: Classification Based over the Route of Administration
  • Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
  • Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
  • Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2018 till 2025
  • Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2018 till 2025
  • Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2018 till 2025
  • Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2018 till 2025
  • Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2018 till 2025
  • Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2018 till 2025
  • Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2018 till 2025
  • Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2018 till 2025
  • Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
  • Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
  • Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
  • Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
  • Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
  • Figure 10-3: Representation of Categories of Liquid Dosage Form
  • Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
  • Figure 10-5: General Forms of Oral Controlled Release System Mechanism
  • Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
  • Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
  • Figure 11-1: Drug Delivery Share by Route of Administration, 2016
  • Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2017 & 2025
  • Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2017 & 2025
  • Figure 11-4: Global - Implantable Device Market (US$ Billion), 2017 & 2025
  • Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2017 & 2025
  • Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2017 & 2025
  • Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2017 & 2025
  • Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2017 - 2025
  • Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
  • Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
  • Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery
Back to Top